A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis

Exclusion Criteria

• •Co-existing Condition:
• •Patients with the following symptoms and conditions are excluded:
• •External ocular infection in the eye to be treated.
• •Other herpetic infections of the retina, toxoplasma, retinochoroiditis, or other disease of the fundus that would preclude assessment of CMV retinitis in the eye to be treated.
• •Ocular conditions that will obstruct visualization of the posterior ocular structures on the eye to be treated.
• •Retinal detachment in the eye to be treated.
• •Ganciclovir implant in the eye to be treated.
• •Known or suspected allergy to phosphorothioate oligonucleotides or intolerance of ISIS 2922.
• •Silicone oil in the eye to be treated.
• •Pseudoretinitis pigmentosa.
• •Syphilis.
• •Patients with the following prior conditions are excluded:
• •History of surgery to correct retinal detachment in the eye to be treated.
• •History of syphilis.
• •1\. Systemic anti-CMV therapies other than oral ganciclovir.
• •Mellaril, Stelazine, chlorpromazine and clofazimine.
• •Combination use of ethambutol and fluconazole.
• •Investigational medications and/or procedures for the treatment of CMV retinitis in the eye to be treated.
• •Ganciclovir implant delivery device in the eye to be treated.
• •Ganciclovir other than oral.
• •Foscarnet.